Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136454) titled 'Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome' on Aug. 14.
Study Type: Expanded Access
Primary Sponsor: Oak Hill Bio Ltd
Condition:
Angelman Syndrome
Intervention:
Drug: Rugonersen
Recruitment Status: Not recruiting
Date of First Enrollment: August 15, 2025
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07136454
Published by HT Digital Content Services with permission from Health Daily Digest....